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Background: India harbors the 3rd highest HIV infected population globally. The magnitude of the HIV detection
challenge is enormous. ELISA is the most commonly used screening technique for HIV. There is always an acute
need for good quality ELISA kits. However, the quality evaluation data on Indian kits are very limited in comparison
with internationally recognized kits. This study aimed to evaluate the performance and diagnostic usefulness of
five commercially available ELISA kits which are frequently used in India.
Findings: The ELISA kits evaluated using an in-house well characterized 100 member sera panel revealed 100%
sensitivity for all the batches. However, batch to batch variation in terms of specificity, positive predictive value
(PPV) and efficiency, although not statistically significant (p > 0.05), was observed. For specificity, the 3rd generation
kits (mean 99.6% to 99.3%) were comparatively better than the 4th generation assays (97.2% to 96.9%). But the 4th
generation kits performed far better in the ability for early detection post HIV infection in the 25 member commercial
seroconversion panel with a margin of at least 22 days and as high as 35 days than the 3rd generation assays.
Conclusions: The commercial ELISA kits with 100% sensitivity seem appropriate for HIV screening. The ability of early
detection post HIV infection favors use of 4th generation kits for ensuring HIV free blood for transfusion. Lot to lot
variations, especially kits having the specificity level ≤98.0%, indicate the need for a regular mechanism of kit
evaluation for each batch for procuring kits appropriate for intended use.
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Background
HIV is a major global public health issue [1]. For assu-
ring a safe blood supply and preventing HIV infection,
proper and accurate detection of HIV is essential [2]. In
India, diagnosis of HIV infection is a major challenge
[3,4]. Several commercial assays are available for detec-
tion of HIV infection. ELISA is the most commonly used
screening assay for HIV [2,5]. A number of ELISA kits
for HIV detection with different principles are available.
Nowadays, in India 3rd generation ELISA are most com-
monly used. The 4th generation assays are based on com-
bined detection of antigen and antibodies simultaneously
and reduce the diagnostic window period further, com-
pared to third generation ELISA which is based on anti-
HIV antibody assay [6-8]. The improved sensitivity for
ELISA is mostly accompanied by a decreased specificity.* Correspondence: sahamk@yahoo.com
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reproduction in any medium, provided the orIn an Indian perspective, limited articles on evaluation
and performance of ELISA kits are available [9] though
HIV testing is being done for a vast numbers of individ-
uals as well as large number of specimens for ensuring
HIV free safe blood for transfusion. Being the 2nd most
populous country with the 3rd largest burden of HIV in
the world [10], the magnitude of HIV testing challenge in
India is enormous and the appropriate response to the
challenge is to ensure the quality of the assay kits suitable
for the intended use. This study aims to evaluate the qua-
lity of commonly available commercial ELISA kits for their
ability to detect HIV suitable for appropriate use in India.Materials and methods
The study was carried out at a National HIV Reference
Laboratory designated for evaluation of diagnostic kits,
including ELISA, in India. A well characterized, 100 mem-
bers, in-house HIV serum panel was used to evaluate and
compare the performance of the kits. The sera used fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.






ELISA 1 ELISA 2 Rapid test Confirmatory test
ICTC HIV Sera Panel
(In-house)
Genetic Systems Genedia HIV Ag-Ab ELISA Rapid 1: Determine HIV1/2 Recombinant
Immunoblot Assay
HIV-1/HIV-2 Green Cross Life
Science Corp. Korea
Inverness Medical
Japan Co. Ltd. Japan
Chiron RIBA HIV-1/HIV-2 SIA
Plus O EIA.
Bio-Rad Laboratories. USA Reactivity range
(pos specimens): 3.503-8.899
Rapid 2: HIV TRI-DOT + Ag Ortho Clinical
Diagnostics Ltd, USA
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from attendees of the Counseling and Testing Centre by
taking informed consent as per the protocol approved by
Institutional Ethical Committee of National Institute of
Cholera and Enteric Diseases. Beside the negative and
positive sera, this serum panel also contained low positive
sera that have shown uniform results in all assays used for
validation. The characterization of in-house panel was
done using United States Food and Drug Administration
(U.S. FDA) or Indian Central Drug Standard Control
Organization (CDSCO) approved kits (Table 1). Sam-
ples non-reactive for all assays were defined as negative
and reactive for all assays were defined as positive mem-
ber in the panel. A commercial seroconversion panel
(Lot# RP-018, Bio-Rad Laboratories, U.S.A) used to evalu-
ate kits consists of a series of 25 specimens collected
from an individual infected with HIV undergoing
seroconversion.Table 2 Performance of HIV ELISA kits with In-house Sera Pan
Total no. of samples Total no. of
lots evaluated
100 5 Lots J. Mitra &
Co. Pvt. Ltd.
Span Diagn
(Confirmed Positive = 40
Confirmed Negative = 6 0)
for each kit Assay result Assay r
Pos Neg Pos
Lot:1 Pos 40 00 40
Neg 00 60 00
Lot:2 Pos 40 01 40
Neg 00 59 00
Lot:3 Pos 40 00 40
Neg 00 0 00
Lot:4 Pos 40 01 40
Neg 00 59 00
Lot:5 Pos 40 00 40
Neg 00 60 00Five batches each of 5 commonly available commercial
ELISA kits, including 3rd and 4th generations, for HIV
detection were evaluated (Table 2). All the kits were
tested and results were validated strictly adhering to
manufacturers’ instruction. The evaluation process main-
tained an unbiased method following a double blind pro-
cedure by using different personnel for pre-analytical and
analytical testing sections. The final analysis of results with
interpretation was done by the laboratory in-charge. The
status of samples was unknown to the persons involved in
pre-analytical and analytical procedures. The performance
of kits was evaluated and compared in terms of sensitivity
([TP/(TP + FN)]×100), specificity ([TN/(TN + FP)]×100),
positive predictive value (PPV = [TP/(TP + FP)]×100),
negative predictive value (NPV = [TN/(TN + FN)]×100)
and efficiency ([(TP + TN)/(TP + FN +TN+ FP)]×100),
where TP = number of true positives, TN = number of true





esult Assay result Assay result Assay result
Neg Pos Neg Pos Neg Pos Neg
01 40 00 40 02 40 02
59 00 60 00 58 00 58
00 40 00 40 02 40 02
60 00 60 00 58 00 58
00 40 00 40 01 40 01
60 00 60 00 59 00 59
00 40 00 40 01 40 03
60 00 60 00 59 00 57
01 40 01 40 02 40 01
59 00 59 00 58 00 59
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to address precision of the proportion estimates and the
degree of confidence was set to 95% [12]. Chi-square
analysis was performed to assess the variation for specifi-
city, PPV and efficiency among different kits as well as in
different batches of same kit.
Results
None of the ELISA kits evaluated was able to identify all
the panel members correctly by all the batches (Table 2).
But all the kits were found to be 100% sensitive in all
the batches. Variation in batches of all the kits was evi-
dent in terms of specificity, PPV and efficiency (Table 3).
ERBA LISA HIV 1 + 2 provided correct results in 4
batches by identifying all panel samples correctly with
99.8% efficiency. Microlisa HIV and Enzaids HIV 1 + 2
both performed equally by correct result only in 3 batches
with 99.6% efficiency. The 4th generation kits, GenscreenTable 3 Performance characteristic of HIV ELISA kits used for







J. Mitra & Co. Pvt. Ltd.
1 100 100 100




Enzaids HIV 1 + 2 ELISA Company:
SPAN Diagnostics Ltd.
1 100 100 98.3




ERBA LISA HIV 1 + 2 Company:
Transasia Bio-medicals Ltd.
1 100 100 100




Genscreen Plus HIV Ag-Ab ELISA
Company: Bio-Rad Laboratories., U.S.A
1 100 100 96.6




Vironostika HIV Ag/Ab Company:
Biomerieux SA. France
1 100 100 96.6




CI: Confidence Interval.and Vironostika, showed the false positivity rates higher
than the 3rd generations, but the variations were not
statistically significant in terms of specificity (χ2 = 0.0683,
df = 4, p > 0.05), PPV (χ2 = 0.1253, df = 4, p > 0.05) and
efficiency (χ2 = 0.0230, df = 4, p > 0.05) of all batches of all
the ELISA kits. The performance of the kits evaluated
using seroconversion panel revealed that all the 3rd gene-
ration kits showed equal sensitivity by detecting HIV
positivity. In contrast, the 4th generation kits, Genscreen
(detected panel member 5, day 16) and Vironostika
(detected member 7, day 29) were significantly more
sensitive and were able to detect HIV positivity 35 and
22 days earlier respectively than the 3rd generation ELISA
kits (Table 4).
Discussion
ELISA is the type of test most commonly used for detec-
tion of HIV particularly for large numbers of specimenscomparative evaluation
Kit Performance









99.3 100 99.0 100 100 100 99.6




99.3 97.6 99.0 100 100 99.0 99.6




99.6 100 99.5 100 100 100 99.8




97.2 95.4 96.2 100 100 98.0 98.4




96.9 95.4 95.8 100 100 98.0 98.2




Table 4 Performance of HIV kits with Seroconversion Panel Sera (Lot# RP-018)
Panel member Bleed day J Mitra & Co. Pvt. Ltd Span Diag. Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Biomerieux
MICROLISA HIV ENZAIDS HIV 1 + 2 ERBALISA GENSCREEN VIRONOSTICA
(S/Co) (S/Co) (S/Co) (S/Co) S/Co)
1 0 0.022 0.235 0.258 0.224 0.238
2 3 0.007 0.162 0.183 0.221 0.15
3 9 0.007 0.177 0.19 0.238 0.112
4 13 0.015 0.148 0.171 0.238 0.254
5 16 0.015 0.162 0.167 2.425 0.233
6 20 0.007 0.162 0.171 2.888 0.258
7 29 0.65 0.877 0.65 3.291 2.002
8 51 6.723 4.401 3.806 9.396 2.265
9 56 7.511 2.523 2.665 12.724 2.436
10 58 7.285 3.65 4.182 14.224 2.967
11 63 5.226 5.549 4.601 16.388 2.95
12 65 7.635 5.069 5.247 17.993 3.245
13 70 6.211 5.339 5.277 19.828 3.026
14 72 6.073 6.419 5.787 20.91 4.513
15 77 6.825 3.552 3.76 21.045 4.189
16 79 7.182 4.639 4.95 22.425 4.472
17 84 7.328 4.177 4.563 22.993 5.386
18 86 7.81 3.953 4.19 22.037 5.729
19 91 5.401 3.639 4.224 23.187 4.72
20 93 7.606 3.964 4.285 23.575 5.604
21 98 7.372 5.141 5.635 23.56 5.976
22 100 6.467 3.469 3.798 24.007 5.988
23 112 7.562 4.372 4.688 29.881 6.254
24 114 7.993 3.776 4.213 24.91 6.537
25 133 8.825 7.415 7.988 24.858 6.625
S/Co = Sample/cut of.
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ELISA kits as well as in different lots of the same kit
(particularly false positive rates), as evident in this study,
highlights an important problem of potentially causing
stress to falsely-positive individuals and may also lead to
additional expenses [13,14]. Hence, evaluation of diag-
nostic ELISA kits gains importance for ensuring the
availability of suitable kits with better performance in
terms of recommended sensitivity and specificity [11], as
in case of blood bank testing where a high degree of sen-
sitivity is also recommended for choosing the testing kit
[11]. Better performance, comparatively, was observed
for ERBALISA kits with 100% efficiency in 4 out of 5
batches (mean efficiency 99.8%). Microlisa and Enzaids
each showed mean efficiency of 99.6%. The performance
of Genscreen and Vironostika was compromised in terms
of specificity, PPV and efficiency as these kits give few
false positive results. The PPV as estimated based on thecomposition of panel sera will change according to the
prevalence in the targeted population to be tested [9].
Thus, in an Indian scenario with 0.27% HIV prevalence
[15], the estimated PPV of the HIV ELISA kits would be
40.30% for both J.Mitra & Co. Pvt. Ltd. and Span Diagnos-
tics Ltd., 57.40% for Transasia Bio-Medicals Ltd. and
14.40% for Bio-Rad Laboratories. The performance of all
five kits in terms of NPV favors their use as a primary
screening assay for HIV infection. Unique combination of
simultaneous Ag-Ab assay gives better performance in a
seroconversion panel as well as reducing the testing
window period by 3.82 days on average [6]. In this study,
Genscreen and Vironostika, both 4th generation assays,
outperformed the 3rd generation ELISA by reducing the
window by 35 and 22 days respectively in the seroconver-
sion panel. Genscreen showed better performance and
identified early seroconversion than Vironostika in
another study [16]. The 3rd generation kits demonstrated
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efficiency of the 4th generation assays is lower, the high
sensitivity demonstrated by the kits may favor them for
HIV screening purposes, because of their early detection
by about 3 weeks post infection. Although lot to lot vari-
ation is evident in the study it is not statistically significant
(p > 0.05), but kits with specificity level <98% are not
recommended for diagnosis of HIV infection in India
according to the national guideline [11].
The panel size is small with 100 members and one sero-
conversion panel only. Kit evaluation with small panel size
may be valuable where studies are limited [17]. Use of a
range of seroconversion panels is essential to test the bio-
logical differences in the timing of appearance of different
antibodies to specific antigens in the host response to the
various HIV antigens in a range of individuals. A more
robust assessment requires the testing of, for example,
10 different seroconversion panels [18,19].
Conclusion
With 100% sensitivity, both the 3rd and 4th generation
commercial ELISA kits seem are appropriate as screen-
ing assay for detection of HIV infection. Earlier detec-
tion post HIV infection favors the use of 4th generation
kits for ensuring HIV free blood for transfusion. The lot
to lot variation in terms of specificity warrants batch
pre-acceptance testing of all new lots or batches of
commercially available ELISA kits in India to ensure that
new batches perform as well as previous ones.
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